Hypogonadism News and Research

RSS

Testicular failure, also known as primary hypogonadism, is an uncommon condition that is characterized by the inability of the testicles to produce sperm and the male hormone testosterone. The are many factors that have been postulated as causes of the condition, which give rise to a wide array of signs and symptoms. These factors can sometimes make diagnosis as well as treatment of testicular failure a challenging problem.

Auxilium Pharmaceuticals reports interim data from XIAFLEX Phase 4 study in patients with DC

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that interim data from its Phase 4 retreatment study (AUX-CC-862) evaluating XIAFLEX (collagenase clostridium histolyticum or CCH) in adult patients with Dupuytren's contracture and a recurrent contracture with a palpable cord will be presented for the first time at the American Association for Hand Surgery 2014 Annual Meeting being held January 8-11, 2014 in Kauai, Hawaii.

9 Jan 2014

Auxilium seeks FDA approval for XIAFLEX sBLA to treat multiple Dupuytren's contracture cords concurrently

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration requesting approval of XIAFLEX (collagenase clostridium histolyticum, or CCH) for the treatment of multiple Dupuytren's contracture cords concurrently.

20 Dec 2013

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.

6 Dec 2013

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada.

11 Oct 2013

Endo Pharmaceuticals' complete response submission to AVEED NDA accepted by FDA

Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. announced today that the U.S. Food and Drug Administration has accepted for review the complete response submission made by Endo to the new drug application for its long-acting testosterone undecanoate injection, AVEED, intended for men diagnosed with hypogonadism.

6 Sep 2013

FDA extends PDUFA goal date for Auxilium Pharmaceuticals' sBLA for XIAFLEX

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has notified the Company that it is extending the Prescription Drug User Fee Act goal date for the Company's supplemental biologics license application for XIAFLEX (collagenase clostridium histolyticum) for the treatment of Peyronie's disease from September 6, 2013 to December 6, 2013.

28 Aug 2013

ADT increases risk of kidney injury in patients with prostate cancer

In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy (ADT) was associated with a significantly increased risk of acute kidney injury, with variations observed with certain types of ADTs, according to a study in the July 17 issue of JAMA.

17 Jul 2013

MHN, Auxilium Pharmaceuticals launch new health awareness program on Peyronie's disease

Men's Health Network and Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, have announced the launch of a new health awareness program called "Ask About the Curve" to provide information about Peyronie's disease and to help empower men to have meaningful discussions about their condition with their partner and their healthcare provider.

11 Jun 2013

FDA issues complete response letter to Endo's NDA for AVEED injection

Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. announced today that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for Endo's long-acting testosterone undecanoate injection, AVEED, for men diagnosed with hypogonadism.

31 May 2013

Research: Heart failure accelerates aging process, brings on early andropausal syndrome

Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times more common in men with heart failure.

27 May 2013

Researchers identify genetic mutations that appear to underlie rare syndrome

Researchers from Massachusetts General Hospital and Duke University have identified genetic mutations that appear to underlie a rare but devastating syndrome combining reproductive failure with cerebellar ataxia - a lack of muscle coordination - and dementia.

9 May 2013

Study: About 42% of screened veterans with blast injuries have irregular hormone levels

Up to 20 percent of veterans returning from Afghanistan and Iraq have experienced at least one blast concussion. New research suggests that nearly half these veterans may have a problem so under-recognized that even military physicians may fail to look for it.

23 Apr 2013

Auxilium Pharmaceuticals reports positive results from phase IIa Frozen Shoulder Syndrome clinical trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive data for collagenase clostridium histolyticum or CCH which is being developed for the potential treatment, if approved by the U.S. Food and Drug Administration, of adult patients with adhesive capsulitis, commonly known as Frozen Shoulder syndrome.

26 Mar 2013

Study: Despite high erectile dysfunction prevalence most patients remain untreated

Despite the high erectile dysfunction prevalence most patients receive no treatment, according to a new US study, presented at the 28th Annual EAU Congress. Undertreatment of ED continues to be common, even though the treatments have a proven efficacy and quality of life impact.

19 Mar 2013

Low testosterone levels occur more often among men on long-acting opioids

Low testosterone levels occur five times more often among men who take long-acting instead of short-acting opioids for chronic pain, according to a new Kaiser Permanente study published in The Clinical Journal of Pain.

2 Feb 2013

ARCHITECT 2nd Generation Testosterone Assay from Abbott

Testosterone is an important androgen hormone in the health and well-being of men and women. Testosterone levels are associated with sexual development, libido, protection against osteoporosis, and cardiovascular health. In men, insufficient testosterone levels (hypogonadism) have been linked to obesity and low libido.

18 Dec 2012

Study finds low testosterone levels among obese teen boys

A study by the University at Buffalo shows for the first time that obese males ages 14 to 20 have up to 50 percent less total testosterone than do normal males of the same age, significantly increasing their potential to be impotent and infertile as adults.

17 Oct 2012

Experimental medication increases muscle strength in cancer patients with low testosterone levels

An experimental medication safely increases muscle strength and physical functioning among cancer patients with low testosterone levels, a new drug study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

Weight loss can reduce prevalence of low testosterone levels in men with prediabetes

Weight loss can reduce the prevalence of low testosterone levels in overweight, middle-aged men with prediabetes by almost 50 percent, a new study finds. Results will be presented Monday at The Endocrine Society's 94th Annual Meeting in Houston.